Biotech

All Articles

iTeos- GSK's TIGIT superstar shows significant enhancement

.After announcing a phase 3 launch based upon favorable midstage results, iTeos and also GSK are act...

More joint FDA can accelerate unusual condition R&ampD: document

.The FDA needs to be much more available as well as collective to discharge a rise in commendations ...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It is actually an unusually busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Reha...

Atea's COVID antiviral fails to stop hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has failed an additional COVID-19 trial, however the biotech still ...

Neurocrine's quote to conserve mental illness possibility stops working

.Neurocrine Biosciences' schizophrenia program pivot has actually stopped working. The biotech was n...

Sanofi pays for $110M upfront for late-stage radioligand treatment

.Sanofi has actually brought in an overdue entry to the radioligand party, paying 100 million euros ...

F 2G brings up $100M for second try to get brand-new antifungal to market

.After F2G's very first effort to obtain a brand-new course of antifungal to market was thwarted by ...

Moderna targets $1.1 B in R&ampD investing slices, drops 5 courses amid profits tensions

.Moderna has actually vowed to cut R&ampD costs by $1.1 billion through 2027. The selection to retra...

Sanofi's $80M bank on Fulcrum dystrophy drug finishes in stage 3 go belly up

.Merely four months after Sanofi bet $80 thousand in beforehand money on Key Therapeutics' losmapimo...

Oncternal equity drains 60% amid cutbacks, trial discontinuations

.Cancer provider Oncternal Therapies is folding all its own clinical tests as well as giving up pers...